Terremoto Biosciences raised $108 million in a Series C financing to advance small-molecule drugs targeting AKT for cancer and rare diseases. The company described its approach as using covalency technologies to produce oral medicines with improved efficacy and safety. The funding includes new backers RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, with participation from existing investors including OrbiMed, Third Rock Ventures, Novo Holdings and Cormorant Asset Management. Terremoto plans a Phase 1 solid-tumor program for TER-2013 and said TER-4480 is set to enter the clinic this year for hereditary hemorrhagic telangiectasia, where no approved therapies exist. In AKT inhibitor development, the round underscores continued investor appetite for mechanism-led oncology assets—particularly those positioned as differentiated on tolerability and duration of response.